Stockscreener 앱 받기
304.96
1.87%
-5.81
시장 영업 전:
304.39
-0.57
-0.19%
전일 마감가:
$310.77
열려 있는:
$319.8
하루 거래량:
1.92M
Relative Volume:
2.10
시가총액:
$14.56B
수익:
$4.03B
순이익/손실:
$-182.84M
주가수익비율:
-81.10
EPS:
-3.7603
순현금흐름:
$391.29M
1주 성능:
+3.04%
1개월 성능:
+5.71%
6개월 성능:
+81.29%
1년 성능:
+74.31%
1일 변동 폭
$300.01
$333.30
1주일 범위
$284.61
$333.30
52주 변동 폭
$146.19
$333.30
Charles River Laboratories International Inc Stock (CRL) Company Profile
명칭
Charles River Laboratories International Inc
전화
781-222-6000
주소
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, NTRA, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
304.96 | 13.98B | 4.03B | -182.84M | 391.29M | -3.7603 |
TMO
Thermo Fisher Scientific Inc
|
656.58 | 241.26B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
215.61 | 150.48B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
400.65 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
169.33 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
436.43 | 42.59B | 3.77B | 449.25M | 240.68M | 7.8556 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-06-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2026-05-29 | 업그레이드 | CLSA | Hold → Outperform |
| 2026-04-14 | 개시 | RBC Capital Mkts | Outperform |
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-11-17 | 업그레이드 | Argus | Hold → Buy |
| 2025-11-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-09-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-05-08 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-03-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-03-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-03 | 업그레이드 | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-11-18 | 다운그레이드 | CLSA | Hold → Underperform |
| 2024-11-07 | 업그레이드 | CLSA | Underperform → Hold |
| 2024-10-23 | 개시 | CLSA | Underperform |
| 2024-10-14 | 개시 | Redburn Atlantic | Sell |
| 2024-10-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-10-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-01 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2024-08-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-08-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | 다운그레이드 | Argus | Buy → Hold |
| 2024-06-07 | 개시 | Mizuho | Neutral |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-02-15 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-09-13 | 개시 | TD Cowen | Market Perform |
| 2023-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-02-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-09-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-08-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | 개시 | Guggenheim | Neutral |
| 2022-04-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-07 | 개시 | Stephens | Overweight |
| 2022-02-17 | 재확인 | BofA Securities | Buy |
| 2022-02-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-02-17 | 재확인 | Deutsche Bank | Buy |
| 2022-02-17 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-17 | 재확인 | UBS | Buy |
| 2021-08-05 | 재개 | Credit Suisse | Neutral |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-07-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-05-13 | 업그레이드 | UBS | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | 개시 | Deutsche Bank | Buy |
| 2020-02-18 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-18 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | 개시 | SVB Leerink | Outperform |
| 2019-04-30 | 재개 | Evercore ISI | Outperform |
| 2018-12-14 | 개시 | Deutsche Bank | Buy |
| 2018-10-09 | 개시 | UBS | Neutral |
| 2018-08-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | 업그레이드 | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
Charles River Laboratories International Inc 주식(CRL)의 최신 뉴스
Charles River Laboratories Stock: Company Reaffirms 2026 Guidance and Sets 2030 Targets - AD HOC NEWS
Charles River Labs Q3 Results: Adj EPS Expected At $2.90$3.00 - scanx.trade
UBS Upgrades Charles River Laboratories International to Buy From Neutral, Adjusts Price Target to $357 From $175 - Moomoo
Halper Sadeh investigates Charles River Labs over fiduciary breaches - scanx.trade
Here's How Much $1000 Invested In Charles River 15 Years Ago Would Be Worth Today - Benzinga
Is Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year? - Zacks Investment Research
UBS resumes Charles River Labs stock coverage with buy rating By Investing.com - Investing.com Australia
UBS resumes Charles River Labs stock coverage with buy rating - Investing.com
UBS Initiates Buy on Charles River Laboratories (CRL) Amid Positive CRO Sector Outlook - GuruFocus
Charles River Laboratories stock pre-market as Cooke & Bieler cites demand stabilization - AD HOC NEWS
Return on invested capital % of Charles River Laboratories International, Inc. – HAN:RV6 - TradingView
Charles River stock: Company reaffirms 2026 guidance and sets 2030 targets - AD HOC NEWS
Demand Stabilization Fuels Charles River Laboratories International’s (CRL) Recovery - Yahoo Finance
Charles River Laboratories International, Inc. Cash Flow – HAN:RV6 - TradingView
Charles River Laboratories stock trades near a yearly high as targets rise - AD HOC NEWS
Charles River Laboratories stock at USD 294.59 on September 28, 2026 - AD HOC NEWS
Should Long Term Growth Targets Require Action From Charles River Labs Stock Investors? - Simply Wall Street
Is Charles River Laboratories Stock Outperforming the S&P 500? - Barchart.com
Barclays Adjusts PT on Charles River Laboratories International to $330 From $300, Keeps Overweight Rating - moomoo.com
Charles River (NYSE:CRL) In Focus As Investor Day Unveils Pathway To Purpose And Lifts Near-Term View - Kalkine Media
Charles River Targets 5%-7% Growth, $300M Savings in 2030 Plan - Yahoo Finance
Charles River Labs stock sets USD 11.45 EPS outlook after Investor Day - AD HOC NEWS
Charles River Laboratories: Positive Investor Day Is Fully Priced In (NYSE:CRL) - Seeking Alpha
Mizuho raises Charles River Labs stock price target to $295 on outlook - Investing.com
RBC Raises Price Target on Charles River Laboratories International to $322 From $282, Keeps Outperform Rating - Yahoo Finance
Evercore ISI Adjusts PT on Charles River Laboratories International to $330 From $320, Maintains Outperform Rating - marketscreener.com
TD Cowen raises Charles River Labs stock price target on growth outlook - Investing.com Canada
Charles River Laboratories (CRL) Stock Still Seems Reasonable Despite Rapid Cell Banking Launch - Yahoo Finance
Charles River Labs stock rises 5.2 percent ahead of the open - AD HOC NEWS
Why Charles River Laboratories (CRL) Stock Is Up Today - Yahoo Finance
A Look at Charles River Laboratories International Inc (CRL) Aft - GuruFocus
Charles River Laboratories (CRL) Reaffirms 2026 Guidance and Unv - GuruFocus
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. : TD COWEN RAISES TARGET PRICE TO $325 FROM $300 - Bitget
CRL: 2030 targets: 5%-7% sales CAGR, ~24% margins, $300M savings, and digital-driven growth - TradingView
CRL: 2030 targets: 5%-7% sales CAGR, 24% margins, and $300M in savings via AI-driven modernization - TradingView
Charles River Laboratories International Jumps 5.1% in Broad Rally - AlphaStreet
Charles River Laboratories International Inc Stock (CRL) Moved Up by 7.23% on Sep 24: Facts Behind the Movement - TradingKey
Charles River Laboratories rises after reaffirming 2026 outlook and unveiling 2030 targets - Quiver Quantitative
Charles River Laboratories International (CRL) As Faster Cell Banking Fuels A Modest Undervalued View - Simply Wall Street
Charles River stock rises on promising 2026 outlook (CRL:NYSE) - Seeking Alpha
Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday - Benzinga
Charles River Laboratories International, Inc. (CRL) Analyst/Investor DaySlideshow (NYSE:CRL) 2026-09-24 - Seeking Alpha
Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day - BioSpace
Charles River Laboratories International, Inc. Investor Day 2026 Transcript - gurufocus.com
Over $300M in savings is expected from 2027 to 2030 as Charles River (CRL) sets a revenue growth target. - Stock Titan
Charles River Labs reiterates FY26 outlook, targets 5-7% growth by 2030 - scanx.trade
Charles River Laboratories stock falls 2.73 percent after Q2 results - AD HOC NEWS
Charles River Laboratories Reaffirms Fiscal 2026 Guidance; Issues 2030 Growth Projections - marketscreener.com
CRL: 2030 targets: 5–7% organic revenue CAGR, ~24% margin, and $300M+ in cost savings - TradingView
CRL: Modernization and digitalization drive growth, with 5–7% organic revenue CAGR targeted by 2030 - TradingView
Charles River Laboratories International Inc (CRL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.99%
0.56%
자본화:
|
볼륨(24시간):